Acceleron Pharma Inc.
NASDAQ: XLRN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Habib Dable
- Employees
- 312
- Headquarters
- Cambridge, United States
- IPO year
- 2013
- Website
- http://www.acceleronpharma.com
Loading XLRN…
Loading profile data…Frequently asked questions about XLRN
What does Acceleron Pharma Inc. (XLRN) do?
Acceleron Pharma Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market treatments for severe and uncommon illnesses. Its flagship product, REBLOZYL (luspatercept-aamt), addresses anemia in adult patients afflicted with beta-thalassemia. The company's pipeline includes additional applications for luspatercep...
Where does XLRN trade?
Acceleron Pharma Inc. (XLRN) trades on the NASDAQ Global Market.
What sector is XLRN in?
Acceleron Pharma Inc. (XLRN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Acceleron Pharma Inc.?
Habib Dable is the chief executive officer of Acceleron Pharma Inc. (XLRN).
Where is Acceleron Pharma Inc. headquartered?
Acceleron Pharma Inc. is headquartered in United States.
Does XLRN pay a dividend?
Acceleron Pharma Inc. (XLRN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did XLRN go public?
Acceleron Pharma Inc. (XLRN) completed its initial public offering in 2013.